European Bronchitol Marketing Application Update
Release Date: 28/09/2011 12:00am
Pharmaxis today announced that the re-examination of the European Bronchitol marketing application for cystic fibrosis by the Committee for Medicinal Products for Human Use (CHMP) is proceeding according to schedule.
The CHMP has adopted a list of questions to be considered by the ad hoc Scientific Advisory Group which was appointed by the CHMP and includes clinicians and experts in the field of cystic fibrosis.Pharmaxis will present to the Scientific Advisory Group in early October and the Scientific Advisory Group will make its recommendations directly to the CHMP.
An opinion on the re-examination of Bronchitol for the treatment of cystic fibrosis is due to be reached by the CHMP at its forthcoming meeting which will be held between 17th and 20th October.
Categories: ASX Announcements